Simulations Plus, Inc. (SLP) bolstered its flagship quantitative systems toxicology (QST) platform with the launch of DILIsym 11. This new release advances drug-induced liver injury (DILI) prediction, with cutting-edge features like pediatric representation and an enhanced T-cell model, solidifying Simulations Plus’s commitment to improving drug safety and patient outcomes.DILIsym 11 introduces several powerful enhancements to extend its predictive reach and improve simulation accuracy. The enhanced version ...